Drugs / ISIS 5132
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00003892 | Feb 1999 → Oct 2000 | ovarian cancer | NCIC Clinical Trials Group | Completed | Missed primary |
| Phase 2 | NCT00003236 | Jul 1998 → Jun 2002 | breast cancer | Eastern Cooperative Oncology Group | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ISIS 5132 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00003236 ↗ |
| Known as | CGP 69846A | “Randomized Phase II Study of Human C-raf Kinase Antisense Oligonucleotide Isis 5132 (CGP 69846A) or Human Pkc-Alpha Antisence Oligonucleotide ISIS 3521 (CGP 64128A) in Women...” NCT00003236 ↗1“Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).” PMID 12694666 ↗ Apr 2003 |
| Modality | Antisense oligonucleotide | “Human C-raf Kinase Antisense Oligonucleotide Isis 5132” NCT00003236 ↗ |
| Route | Intravenous | “Patients receive ISIS 5132 IV continuously over 21 days.” NCT00003236 ↗ |
| Target | RAF1 | “Human C-raf Kinase Antisense Oligonucleotide Isis 5132” NCT00003236 ↗ |